Role of liquid biopsy in the detection and monitoring of cervical cancer

Cervical cancer is one of the most common cancers among women of reproductive age. The cytological screening is not always effective and appropriate, therefore the search for new predictive markers of the cervical cancer are of great importance. there are no biomarkers for monitoring patients previously treated for cervical cancer. liquid biopsy is a new option of personalized approach to the detection and monitoring of cervical cancer. it is a set of methods for determining the derivatives of a tumor in biological media, most often in the blood: circulating tumor cells, circulating dNa, RNa, exosomes, etc.The purpose of the studywas to analyze data on the role of liquid biopsy in the diagnosis and monitoring of cervical cancer.Material and methods. We analyzed publications available from pubmed, Elibrary over the past 10 years.Results. Circulating tumor cells, circulating tumor dNa and exosomes are the most studied cancer non-invasive biomarkers. these circulating biomarkers play a key role in the understanding of cervical carcenogenesis, chemo-and radioresistance. currently, liquid biopsy is considered as a promising modern method for the detection and monitoring of cervical cancer. the diagnostic efficiency of this method is good, so it can be used for cervcal cancer screening. However, such statements require further research in this direction. in addition, given the emerging information on the molecular carcinogenesis of cervical cancer, liquid biopsy can also be used as a basis for the development of targeted therapy for locally advanced and generalized cervical cancer.Conclusion. Liquid biopsy is the non-invasive method of cervical cancer monitoring.

Download Full-text

Clinical Significance of Circulating Tumor Cells in Gastrointestinal Carcinomas

Diagnostics ◽

10.3390/diagnostics10040192 ◽

2020 ◽

Vol 10 (4) ◽

pp. 192

Author(s):

Leonie Konczalla ◽

Anna Wöstemeier ◽

Marius Kemper ◽

Karl-Frederik Karstens ◽

Jakob Izbicki ◽

...

Keyword(s):

Tumor Cells ◽

Circulating Tumor Cells ◽

Clinical Application ◽

Liquid Biopsy ◽

Cancer Diagnostics ◽

Therapeutic Approaches ◽

Primary Tumors ◽

New Therapeutic Approaches ◽

Tumor Dissemination

The idea of a liquid biopsy to screen, surveil and treat cancer patients is an intensively discussed and highly awaited tool in the field of oncology. Despite intensive research in this field, the clinical application has not been implemented yet and further research has to be conducted. However, one component of the liquid biopsy is circulating tumor cells (CTCs) whose potential for clinical application is evaluated in the following. CTCs can shed from primary tumors to the peripheral blood at any time point during the progress of a malignant disease. Following, one single CTC can be the origin for distant metastasis at later cancer stage. Thus, CTCs have great potential to either be used in cancer diagnostics and patient stratification or to function as a target for new therapeutic approaches to stop tumor dissemination and metastasis at the very early beginning. Due to the biological fundamental role of CTCs in tumor progression, here, we provide an overview of CTCs in gastrointestinal cancers and their potential use in the clinical setting. In particular, we discuss the usage of CTC for screening and stratifying patients’ risk. Moreover, we will discuss the potential role of CTCs for treatment specification and treatment monitoring.

Download Full-text

The role of liquid biopsies in prostate cancer management

Lab on a Chip ◽

10.1039/d1lc00485a ◽

2021 ◽

Author(s):

Chi-Ju Kim ◽

Liang Dong ◽

Sarah Amend ◽

Yoon-Kyoung Cho ◽

Kenneth Pienta

Keyword(s):

Prostate Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Cancer Diagnosis ◽

Liquid Biopsy ◽

Liquid Biopsies ◽

Cancer Management ◽

The Common ◽

Prostate Cancer Management

Liquid biopsy has emerged as a complement to invasive tissue biopsy to guide cancer diagnosis and treatment. The common liquid biopsy biomarkers are circulating tumor cells (CTCs), extracellular vesicles (EVs),...

Download Full-text

The role of circulating tumor cells and K-ras mutations in patients with locally advanced rectal cancer: a prospective study

Molecular Biology Reports ◽

10.1007/s11033-020-05973-8 ◽

2020 ◽

Vol 47 (12) ◽

pp. 9645-9657

Author(s):

Abeer A. Bahnassy ◽

Yasser A. Abdel-Azim ◽

Somaya Ezzat ◽

Mona S. Abdellateif ◽

Abdel-Rahman N. Zekri ◽

...

Keyword(s):

Rectal Cancer ◽

Prospective Study ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Locally Advanced ◽

Advanced Rectal Cancer ◽

Locally Advanced Rectal Cancer ◽

Ras Mutations ◽

A Prospective Study

Download Full-text

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as a Liquid Biopsy Marker in Colorectal Cancer

Cancers ◽

10.3390/cancers13184500 ◽

2021 ◽

Vol 13 (18) ◽

pp. 4500

Author(s):

Isabel Heidrich ◽

Thaer S. A. Abdalla ◽

Matthias Reeh ◽

Klaus Pantel

Keyword(s):

Colorectal Cancer ◽

Disease Progression ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Liquid Biopsy ◽

Personalized Therapy ◽

Liquid Biopsies ◽

Curative Surgery ◽

Non Invasive ◽

Staging Systems

Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. It is a heterogeneous tumor with a wide genomic instability, leading to tumor recurrence, distant metastasis, and therapy resistance. Therefore, adjunct non-invasive tools are urgently needed to help the current classical staging systems for more accurate prognostication and guiding personalized therapy. In recent decades, there has been an increasing interest in the diagnostic, prognostic, and predictive value of circulating cancer-derived material in CRC. Liquid biopsies provide direct non-invasive access to tumor material, which is shed into the circulation; this enables the analysis of circulating tumor cells (CTC) and genomic components such as circulating free DNA (cfDNA), which could provide the key for personalized therapy. Liquid biopsy (LB) allows for the identification of patients with a high risk for disease progression after curative surgery, as well as longitudinal monitoring for disease progression and therapy response. Here, we will review the most recent studies on CRC, demonstrating the clinical potential and utility of CTCs and ctDNA. We will discuss some of the advantages and limitations of LBs and the future perspectives in the field of CRC management.

Download Full-text